drug · intermediate · partly written
Tisagenlecleucel (Kymriah)
Tisagenlecleucel is an autologous CD19-directed CAR T cell product approved for B-cell leukemia and lymphomas.
Also called: Kymriah, CTL019
This describes published medicine for readers who want to understand how it works and what happened. It is not medical advice and says nothing about what any person should take.
What it is in one breath
A living drug made from the patient's own T cells. A gene for a receptor aimed at CD19 is added outside the body, the cells are multiplied and given back by drip. In the decisive trial 81% of 75 young patients with relapsed leukemia went into remission within three months. 12
Reported, not yet replicated
The decisive trial: ELIANA more
ELIANA was a phase 2, single-cohort, 25-centre global study in children and young adults with CD19-positive relapsed or refractory B-cell acute lymphoblastic leukemia. The primary end point was overall remission (complete remission or complete remission with incomplete count recovery) within 3 months. Of 75 infused patients evaluable for efficacy, 81% reached it, and all responders were minimal-residual-disease negative by flow cytometry. Event-free survival was 73% (95% CI 60 to 82) at 6 months and 50% (95% CI 35 to 64) at 12; overall survival 90% and 76%. The median duration of remission had not been reached. Persistence in blood was seen as long as 20 months.
Denominators move. In the FDA review ELIANA had 107 consented, 88 enrolled and 68 treated; the agency's efficacy set was 63 patients, with complete remission 63% and overall remission 82.5%, and about 9% (7 of 78) of cell lots failed manufacturing. Read which denominator a rate uses. 12
Reported, not yet replicated
How it is made and what the cell carries more
Blood cells are taken by leukapheresis, T cells are activated, a lentiviral vector inserts the CAR gene into the cell's DNA, the cells expand and are returned. Because the gene integrates, every daughter cell inherits it: this is why one infusion can keep working. The receptor's outside is a mouse-derived antibody fragment against CD19; inside are CD3 zeta and a 4-1BB costimulatory domain, which the FDA review describes as important for persistence.
Lymphodepleting chemotherapy is given before the infusion (see concepts/lymphodepletion). The reason is expansion, not rejection of own cells: in a lymphoma study of 32 adults, cyclophosphamide plus fludarabine gave more CAR T expansion and persistence than cyclophosphamide alone. 23
Reported, not yet replicated
Why the body does not reject it more
The cells are the patient's own and carry the patient's HLA, so there is no donor-versus-host mismatch (see concepts/graft-rejection-and-immunosuppression). The one foreign part is the mouse-derived binder: the FDA review reports antibodies against it before infusion in 86% of patients and induced or boosted antibodies in 37%, with no apparent effect on expansion, response or relapse in that study. 2
Reported, not yet replicated
How long it lasts deep
ELIANA saw persistence in blood up to 20 months. For a different CD19 CAR product in two patients with chronic lymphocytic leukemia, CAR T cells were still detectable more than ten years after infusion; that is two patients and a different construct, so it shows a possibility, not a rate for this drug. 14
Reported, not yet replicated
Class safety warning deep
On 28 Nov 2023 FDA said it was investigating reports of T-cell malignancies, including CAR-positive lymphoma, after BCMA- or CD19-directed autologous CAR T therapies, and required 15-year follow-up. The agency kept the view that benefit outweighs risk for approved uses. 5
Reported, not yet replicated
Modality
Targets
Pathways
Indications
Identifiers
Nct eliana
NCT02435849
Mechanism
A patient's own T cells are collected, a lentiviral vector inserts a gene for a chimeric antigen receptor, and the cells are expanded and returned. The receptor has an outer mouse-derived antibody fragment that binds CD19, plus CD3 zeta (the go signal) and a 4-1BB costimulatory domain inside. When the cell meets CD19 on a B cell or B-cell cancer it activates, kills and divides. Normal B cells carry CD19 too and die as well. 21
Reported, not yet replicated
Delivery route
Must survive
Manufacture and shipping first: about 9% of cell lots failed in the FDA review of ELIANA data (7 of 78). Then the cells must expand in a lymphocyte-depleted host and home by themselves through blood to marrow, nodes and tumour; the patient's own HLA means the cells are not rejected as a foreign graft. The leftover foreign part is the mouse sequence in the CAR: the FDA review reports antibodies against it before infusion in 86% of patients and induced or boosted in 37%, with no apparent effect on expansion, response or relapse in that study. 2
Reported, not yet replicated
Side effects
Cytokine release syndrome
Occurred in 77% of 75 infused patients in ELIANA; 48% of those received tocilizumab. The FDA review gives 79% in a smaller set of 68. 12
Reported, not yet replicated
Neurologic events
40% in the ELIANA abstract, managed with supportive care, no cerebral edema reported. The FDA review gives a higher figure (65%) for its 68-patient set; the two use different denominators and event definitions. 12
Reported, not yet replicated
Grade 3 or 4 treatment-related adverse events
73% of patients in ELIANA. 1
Reported, not yet replicated
B-cell aplasia with low antibodies (hypogammaglobulinemia)
Expected, because normal B cells also carry CD19. 2
Reported, not yet replicated
T-cell malignancies, class warning
FDA stated on 28 Nov 2023 that it had reports of T-cell malignancies including CAR-positive lymphoma after BCMA- or CD19-directed autologous CAR T products; it applies to all approved products of the class and the agency judged benefit to outweigh risk for approved uses. Postmarketing follow-up of 15 years is required. 5
Reported, not yet replicated
Verdict
Outcome
worked
Why
In ELIANA (phase 2, single arm, 25 centres) 75 infused children and young adults with relapsed or refractory B-cell ALL could be evaluated: remission within 3 months 81%, all responders negative for minimal residual disease; event-free survival 73% at 6 months and 50% at 12; overall survival 90% and 76%; persistence in blood up to 20 months. It was approved by FDA in 2017. The comparison is not randomised, so the benefit is judged against historical outcomes. 16
Reported, not yet replicated
Teach this
In one sentence
Tisagenlecleucel is the patient's own T cells given a gene for a CD19-seeking receptor, multiplied outside the body and infused once. 12
Reported, not yet replicated
The five-minute version
Cells are collected, engineered with a lentiviral vector, expanded and returned after lymphodepleting chemotherapy. They find CD19 on B cells and leukemia cells, kill them and multiply. In ELIANA 81% of 75 infused young patients were in remission within three months and the cells persisted up to 20 months. The same activation causes cytokine release syndrome (77%) and neurologic events (40%). 12
Reported, not yet replicated
The common wrong idea
CAR T cells are foreign cells, so the body must be held back from rejecting them.
They are the patient's own cells; the chemotherapy before infusion makes room for them to multiply and is not there to stop rejection.
The one citation to hand over: 1
Still open here
- Antigen escape (loss of CD19 by the tumour): no rate was found in the sources opened.
- ELIANA is single arm; durability beyond the follow-up in the opened abstract and the current label text were not read (only the FDA review and an abstract).
Not yet written: Assays used, Off targets.
Linked from
Sources
- Maude, S. L., et al.. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. New England Journal of Medicine (2018). paper; opened 2026-11-17 all records citing this
- FDA Summary Basis for Regulatory Action: Kymriah (tisagenlecleucel). FDA (2017). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Turtle, C. J., et al.. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells. Science Translational Medicine (2016). paper; opened 2026-11-17 all records citing this
- Melenhorst, J. J., et al.. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature (2022). paper; opened 2026-11-17 all records citing this
- FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous CAR T Cell Immunotherapies. FDA (2023). regulatory, not peer reviewed; opened 2026-11-17 all records citing this
- Kymriah (tisagenlecleucel): FDA product page. FDA. regulatory, not peer reviewed; opened 2026-11-17 all records citing this
Where it sits on the map
History of this record (1)
This record has been changed 1 time, on the dates below. The note kept against each change is written for the people who maintain the atlas, in their own shorthand, so it is not shown here; it is in the record itself.
- Year
- 2017
- Regulatory status
- approved
- Status
- partly written
- Last updated
- 2026-11-17
- Record
- content/drugs/tisagenlecleucel.json